Bayer and Genaissance eye individualised medicine:
This article was originally published in Clinica
Executive Summary
Bayer Diagnostics has formed a deal with Genaissance Pharmaceuticals to develop diagnostic tests for determining adverse drug response and efficacy response to existing drug classes and new drug products. Genaissance will apply its haplotype technology, HAP, to Bayer's clinical samples in order to identify diagnostic markers and therapeutic targets for individualised medicine. Bayer will receive exclusive rights to develop and market tests based on the results of the collaboration. Genaissance will receive royalties and rights to perform these tests in its CLIA-certified diagnostic laboratory. There are mutual royalty provisions for any drugs derived from the co-operation.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.